Report #2835383

Received Apr 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: SC
Recovered: Unknown
Vaccinated: Dec 31, 2024
Onset: Feb 1, 2025
Days to onset: 32
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	—

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

Received Heplisav-B and then Received Twinrix; Initial report received on 31-Mar-2025. A pharmacist reported that a 56-year-old male (race, ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and received TWINRIX as the second dose. No medical history or concomitant medication were reported. On 31-Dec-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (Lot #, expiration date, NDC#, site and route not reported)]. On 01-Feb-2025, the patient received dose 2 of a hepatitis B vaccine [TWINRIX (Lot # M4B34, expiration date 28-Sep-2026, NDC # not reported)] intramuscularly in the left arm. TWINRIX was given at a different pharmacy due to the patient's insurance coverage. No adverse effects were reported. No additional information was provided. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.